Memantina Sun

Memantine, the active ingredient in Memantina Sun, is a NMDA receptor antagonist presented as an oral formulation for oral use. It reduces glutamate‑mediated excitotoxicity in the brain and is employed to treat moderate to severe Alzheimer’s disease, helping to improve cognition, behavior, and daily functioning in affected patients.

GNH USA supplies Memantina Sun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU GMP standards and provides reliable logistics for global distribution.

Memantine is an NMDA receptor antagonist that modulates glutamatergic activity and is indicated for the treatment of cognitive decline associated with neurodegenerative conditions, most notably Alzheimer’s disease.

Alzheimer's disease (moderate to severe): Improves cognition, behavior, and functional abilities in patients with moderate to severe disease. Behavioral symptoms of Alzheimer’s disease: Reduces agitation and aggression in affected individuals. Functional impairment in Alzheimer’s disease: Supports activities of daily living and slows functional decline.

Memantine may be associated with several adverse reactions, ranging from mild to serious.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Confusion: occasional disorientation. - Hypertension: modest increase in blood pressure. - Insomnia: difficulty falling or staying asleep.

Serious or Rare Side Effects: - Seizures: potential for convulsive episodes. - Hallucinations: visual or auditory disturbances. - Cardiac arrhythmia: irregular heart rhythm. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hepatic dysfunction: elevated liver enzymes or jaundice.

Before initiating therapy, consider the following precautions. - Renal impairment: dose adjustment may be required in patients with reduced kidney function. - Hepatic impairment: use with caution in severe liver disease. - Concomitant NMDA antagonists: avoid combining with other NMDA‑blocking agents. - History of seizures: monitor closely for increased seizure risk. - Pregnancy and lactation: safety not established; prescribe only if benefit outweighs potential risk. - Store below 25°C: keep in the original pack, protect from moisture.

Memantine can interact with several medicines; interactions are categorized by clinical significance.

Major Interactions (Avoid): - Amantadine: combined NMDA antagonism may increase toxicity. - Strong CYP3A4 inhibitors: may raise memantine plasma concentrations. - Probenecid: reduces renal clearance, leading to higher exposure.

Moderate Interactions (Monitor Closely): - NSAIDs: may increase risk of edema. - Anticholinergic agents: additive cognitive impairment. - Antihypertensives: potential enhancement of blood‑pressure‑lowering effect. - Diuretics: monitor electrolyte balance. - SSRIs: possible increase in serotonergic side effects.